All In Biotech

Drug Trial Radar · NCT07710027

Identification of a Safe and Non-Psychedelic Dose of Psilocybin

A Randomized, Double-Blind, Single Ascending Dose Study to Identify a Safe and Non-Psychedelic Dose of Psilocybin

Last checked: Nov 20, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Oct 19, 2021

Primary completion

Mar 12, 2022

Study completion Mar 12, 2023

Sponsor

Lead sponsor
Diamond Therapeutics Inc.Industry
Sponsor type
Industry
Collaborators
BioPharma Services Inc.
First posted
Jul 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This randomized, double-blind, placebo-controlled, single ascending dose study will evaluate psilocybin in healthy adult subjects. Each subject will complete Screening within 28 days before admission, a 3-day/2-night inpatient Treatment Phase from Day -1 to Day 2, and Follow-Up 7±2 days after dosing. Up to 80 subjects will be enrolled in up to 10 cohorts of 8 subjects. In each cohort, 6 will receive a single oral dose of psilocybin and 2 matching placebo. The first cohort will receive 0.5 mg psilocybin or placebo. The DSRC will determine subsequent dose levels after each completed cohort. Proposed doses are 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, and up to 5 mg; lower doses, repeated levels, or smaller increments such as 0.25 mg may be used based on emerging data. Within each cohort, safety and pharmacodynamic data will be collected through 24 hours post dose. Safety monitoring will include adverse events, vital signs, ECGs, laboratory tests, physical examinations, concomitant medications, and C-SSRS results. Pharmacokinetic blood samples will be collected before and after dosing, and blood for possible retrospective pharmacogenetic analysis will be collected on Day -1. Pharmacodynamic assessments will include Alertness/Drowsiness, Agitation/Relaxation, Hallucinations, Any Effects, Bowdle, Bond-Lader, 5D-ASC, and STAI measures. Cognitive and psychomotor testing will include RTI, RVP, and SWM tasks. Pupil diameter will be measured as an objective marker. Other subject-reported effects may be recorded as adverse events at the investigator's discretion. Subjects will be discharged on Day 2 if medically appropriate and will receive a 24-hour/7-day emergency clinic contact number. After each cohort, the DSRC will review available blinded safety and pharmacodynamic data through 24 hours post dose before the next cohort begins. Escalation and any decision to stop will follow prespecified rules. The study aims to identify a safe threshold dose (TD) that does not elicit psychoactive effects. The TD will be the dose immediately before the dose at which escalation stops because of neuropsychiatric adverse events and/or a pharmacodynamic response pattern indicating a dose above the nonpsychoactive level. The study will end when a TD is identified or the 5 mg maximum dose is reached.

Conditions

  • Healthy Controls

Interventions

  • Psilocybin (low dose) or PlaceboDrug

    Single ascending dose escalation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Safety Event FrequencyTime frame: Monitoring from dosing through treatment (3 days) and Follow-Up (~1 week).
  2. Clinical Safety Event SeverityTime frame: Monitoring from dosing through treatment (3 days) and Follow-Up (~1 week).
  3. Clinical Safety Event Relationship to TreatmentTime frame: Monitoring from dosing through treatment (3 days) and Follow-Up (~1 week).
  4. Vital Signs Heart Rate for Clinical Safety and TolerabilityTime frame: Vital signs 0.5, 1, 1.5, 2, 3, 6, 8, 10, 12 hours after dose.
  5. Electrocardiogram for Clinical Safety and TolerabilityTime frame: ECG baseline and 3 and 6 hours after dosing.
  6. Five-Dimensional Altered States of Consciousness ScaleTime frame: The 5D-ASC will be administered 6 hours following dosing.
  7. State Trait Anxiety Inventory ScaleTime frame: The STAI will be given at baseline and at the two and six hour time points following dose.
  8. Reaction Time Test PerformanceTime frame: Reaction time test will be given at baseline and at the two and six hour time points following dosing.
  9. Rapid Visual Information Processing TestTime frame: Rapid Visual Information Processing test will be given at baseline and at the two and six hour time points following dosing. Performance will be measured as change from baseline across time and to maximum or minimum effect .
  10. Spatial Working MemoryTime frame: The Spatial Working Memory (SWM) test will be given at baseline and at the two and six hour time points following dosing. Performance will be measured as change from baseline across time.
  11. Perceptual Pharmacodynamic Alertness Drowsiness Visual Analog ScaleTime frame: The Alertness/Drowsiness VAS will be given at baseline, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours after dosing.
  12. Perceptual Pharmacodynamic Agitation Relaxation Visual Analog ScaleTime frame: The Agitation/Relaxation VAS will be given at baseline, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours after dosing.
  13. Perceptual Pharmacodynamic Any Drug Effects Visual Analog ScaleTime frame: The Any Drug Effects VAS will be given at baseline, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours after dosing.
  14. Perceptual Pharmacodynamic Hallucinations Visual Analog ScaleTime frame: The Hallucainations VAS will be given at baseline, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours after dosing.
  15. Perceptual Pharmacodynamic Bowdle (internal and external perceptions) Visual Analog ScaleTime frame: The Bowdle VAS will be given at baseline, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours after dosing.
  16. Perceptual Pharmacodynamic Bond-Lader Visual Analog ScaleTime frame: The Bond-Lader VAS will be given at baseline, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours after dosing.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • BioPharma Services Inc.

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.